Azadeh Abravan

Azadeh Abravan is a Research Fellow at the University of Manchester, based at the Christie NHS Foundation Trust. She specializes in radiation oncology and data-driven approaches to predict treatment toxicity in cancer patients. Her current focus is identifying high-risk patients for cardiopulmonary toxicity post-thoracic radiotherapy using advanced analytics. She holds affiliations with the Manchester Cancer Research Centre and contributes to UN Sustainable Development Goals related to health equity and innovation.

Her research interests include pre-existing multimorbidity analysis, hematological toxicity prediction, and big data applications in oncology. She has published over 38 peer-reviewed articles, with key contributions in journals like Journal of Thoracic Oncology and British Journal of Radiology. Her work explores dose-response relationships in radiation therapy, causal inference methodologies, and clinical outcomes modeling.

Azadeh has received prestigious awards including the Elsevier Young Researcher Award 2023 and the Highlights of Proffered Papers - Best Physics Paper (ESTRO2019). She actively engages in professional development initiatives, such as mentoring programs for early-career radiation oncology professionals across Europe. Her collaborative projects span institutions globally, emphasizing interdisciplinary approaches to improve cancer care strategies.

Notable research highlights include studies on lymphopenia effects on lung cancer survival, CT-based radiomic frameworks for lung cancer, and cardiac toxicity mitigation via dose optimization. Her work bridges clinical practice and data science, aiming to refine personalized treatment strategies while minimizing adverse effects.